{
    "clinical_study": {
        "@rank": "16441", 
        "arm_group": [
            {
                "arm_group_label": "evaluated vaccine", 
                "arm_group_type": "Experimental", 
                "description": "0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)"
            }, 
            {
                "arm_group_label": "imported compared vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)"
            }, 
            {
                "arm_group_label": "domestic compared vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to observe the adverse reaction ratio and hemagglutination\n      inhibition (HI) antibody positive rate, Geometric mean titer (GMT) of three brands split\n      influenza virus vaccine in different population."
        }, 
        "brief_title": "Safety and Immunogenicity Study of Split Influenza Virus Vaccine in Different Age Groups", 
        "completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "Observational Objectives:\n\n      To describe the safety of evaluated vaccine, given in the two-dose schedule in accordance\n      with the Package Insert, in children aged \u2265 6 months to \u2264 36 months,6th to 12th birthday and\n      \u2265 60th birthday.\n\n      To describe the immunogenicity of evaluated vaccine, given in the two-dose schedule in\n      accordance with the Package Insert, in children aged \u2265 6 months to \u2264 36 months, 6th to 12th\n      birthday and \u2265 60rd birthday."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  participants were enrolled (toddlers: 6 months to 3 years; school-aged children:  6\n             to 12 years and older adults:  \u226560 years\uff09\n\n          -  Eligible participants were generally healthy or had stable chronic medical conditions\n             (for older adults only)\n\n        Exclusion Criteria:\n\n          -  History of allergic reaction to any component of the study vaccines or previous\n             influenza vaccine\n\n          -  History of systemic hypersensitivity to hens' eggs\n\n          -  History of Guillain Barr\u00e9 syndrome following administration of any influenza vaccine\n\n          -  Any immunodeficient or immunocompromised conditions\n\n          -  Receipt of cytotoxic or immunosuppressive drugs within the past 6 months\n\n          -  Receipt of blood-derived product within the past 3 months\n\n          -  Receipt of any vaccine within one month prior to study entry with exception of\n             paediatric routine vaccination\n\n          -  Receipt of non-study 2010-2011 seasonal TIV\n\n          -  Participation in any other study with a non-approved drug during the study\n\n          -  Acute febrile disease and other self-limiting illness were the temporary exclusion\n             criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "900", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654809", 
            "org_study_id": "BJCDPC-1"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "evaluated vaccine", 
                    "imported compared vaccine", 
                    "domestic compared vaccine"
                ], 
                "description": "0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)", 
                "intervention_name": "evaluated vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "evaluated vaccine", 
                    "imported compared vaccine", 
                    "domestic compared vaccine"
                ], 
                "description": "0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)", 
                "intervention_name": "imported compared vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "evaluated vaccine", 
                    "imported compared vaccine", 
                    "domestic compared vaccine"
                ], 
                "description": "0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)", 
                "intervention_name": "domestic compared vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 30, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Langfang", 
                        "country": "China", 
                        "state": "Hebei"
                    }, 
                    "name": "Sanhe Centre for Disease Control and Prevention"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baotou", 
                        "country": "China", 
                        "state": "Inner Mongolia"
                    }, 
                    "name": "Jiuyuan Center for Disease Control and Prevention"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Evaluation of Safety and Immunogenicity Among Different Age-groups Receiving Different Split Influenza Vaccines", 
        "overall_official": {
            "affiliation": "Beijing Chaoyang District Center for Disease Control and Prevention", 
            "last_name": "Nianmin Shi, Master", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The immunologic equivalence of 7days after vaccination of influenza virus vaccine was measured in terms of GMTs.", 
                "measure": "To evaluate the immunogenicity of evaluated vaccine", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "The incidence of adverse events was analyzed statistically", 
                "measure": "To evaluate the safety", 
                "safety_issue": "Yes", 
                "time_frame": "4 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654809"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Beijing Center for Disease Control and Prevention", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Center for Disease Control and Prevention", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}